These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 22121234)

  • 1. A case-control study of calciphylaxis in Japanese end-stage renal disease patients.
    Hayashi M; Takamatsu I; Kanno Y; Yoshida T; Abe T; Sato Y;
    Nephrol Dial Transplant; 2012 Apr; 27(4):1580-4. PubMed ID: 22121234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors and mortality associated with calciphylaxis in end-stage renal disease.
    Mazhar AR; Johnson RJ; Gillen D; Stivelman JC; Ryan MJ; Davis CL; Stehman-Breen CO
    Kidney Int; 2001 Jul; 60(1):324-32. PubMed ID: 11422768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study.
    Liu Y; Zhang X; Xie X; Yang X; Liu H; Tang R; Liu B
    Ren Fail; 2021 Dec; 43(1):406-416. PubMed ID: 33641601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The calciphylaxis syndrome as a complication of chronic kidney failure. 6 case reports and literature review].
    Válek M; Sulková S; Schestauberová E; Svára F; Mann H; Polakovic V
    Cas Lek Cesk; 2002 Jun; 141(11):355-8. PubMed ID: 12099060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertension in hemodialysis patients in Andalucia].
    García Cortés MJ; Ceballos M;
    Nefrologia; 2004; 24(2):149-57. PubMed ID: 15219090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcific uraemic arteriolopathy (calciphylaxis): incidence, clinical features and long term outcomes].
    Esteve V; Almirall J; Luelmo J; Sáez A; Andreu X; García M
    Nefrologia; 2007; 27(5):599-604. PubMed ID: 18045036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calciphylaxis in end-stage renal disease patients.
    Verdalles U; García de Vinuesa S; Luño J
    Nephrol Dial Transplant; 2012 Sep; 27(9):3663; author reply 3663-4. PubMed ID: 22805222
    [No Abstract]   [Full Text] [Related]  

  • 9. Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases.
    Savoia F; Gaddoni G; Patrizi A; Misciali C; Odorici G; Tampieri G; Tampieri E; Cantelli S; Aldi M
    G Ital Dermatol Venereol; 2013 Oct; 148(5):531-6. PubMed ID: 24005147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current state of chronic dialysis treatment in Japan (as of December 31, 2000).
    Ther Apher Dial; 2003 Feb; 7(1):3-35. PubMed ID: 12921111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous necrosis by calcific uremic arteriolopathy.
    Galimberti RL; Farias Edos R; Parra IH; Algranati L; Kowalczuk A; Imperiali N; Greloni GC; Galimberti G
    Int J Dermatol; 2005 Feb; 44(2):101-6. PubMed ID: 15689205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calciphylaxis in CKD and beyond.
    Brandenburg VM; Kramann R; Specht P; Ketteler M
    Nephrol Dial Transplant; 2012 Apr; 27(4):1314-8. PubMed ID: 22344774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calciphylaxis: natural history, risk factor analysis, and outcome.
    Weenig RH; Sewell LD; Davis MD; McCarthy JT; Pittelkow MR
    J Am Acad Dermatol; 2007 Apr; 56(4):569-79. PubMed ID: 17141359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates.
    Hanafusa T; Yamaguchi Y; Tani M; Umegaki N; Nishimura Y; Katayama I
    J Am Acad Dermatol; 2007 Dec; 57(6):1021-5. PubMed ID: 18021849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute calciphylaxis precipitated by the initiation of hemodialysis.
    Sandhu G; Casares P; Ranade A; Jones J; Amar LI; Guisado D; Chan G; Smith SD
    Clin Nephrol; 2013 Oct; 80(4):301-5. PubMed ID: 22762780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis.
    Sulková SD; Válek M
    Nutrition; 2010 Sep; 26(9):910-4. PubMed ID: 20692603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calciphylaxis: one hospital's experience.
    Barton A; Brownrigg R
    J CANNT; 1998; 8(4):29-33, 35-9; quiz 34, 40-1. PubMed ID: 10196930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients.
    Stack AG; Bloembergen WE
    Am J Kidney Dis; 2001 Nov; 38(5):992-1000. PubMed ID: 11684552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.